Your search returned 8 results.

Results
	1.	No difference in between-country variability in use of newly approved orphan and non- orphan medicinal products--a pilot study. [electronic resource] by Stolk, Pieter Heemstra, Harald E Leufkens, Hubert G M Bloechl-Daum, Brigitte Heerdink, Eibert R Producer: 20100312 In: Orphanet journal of rare diseases vol. 4 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in the Netherlands. [electronic resource] by Heisen, Marieke Treur, Maarten J Heemstra, Harald E Giesen, Eric B W Postma, Maarten J Producer: 20180507 In: Journal of medical economics vol. 20 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	3.	Predictors of orphan drug approval in the European Union. [electronic resource] by Heemstra, Harald E de Vrueh, Remco L van Weely, Sonja Büller, Hans A Leufkens, Hubert G M Producer: 20080731 In: European journal of clinical pharmacology vol. 64 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	4.	Translation of rare disease research into orphan drug development: disease matters. [electronic resource] by Heemstra, Harald E van Weely, Sonja Büller, Hans A Leufkens, Hubert G M de Vrueh, Remco L A Producer: 20100319 In: Drug discovery today vol. 14 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	5.	Orphan drug development across Europe: bottlenecks and opportunities. [electronic resource] by Heemstra, Harald E de Vrueh, Remco L A van Weely, Sonja Büller, Hans A Leufkens, Hubert G M Producer: 20081204 In: Drug discovery today vol. 13 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	6.	Safety-related regulatory actions for orphan drugs in the US and EU: a cohort study. [electronic resource] by Heemstra, Harald E Giezen, Thijs J Mantel-Teeuwisse, Aukje K de Vrueh, Remco L A Leufkens, Hubert G M Producer: 20100225 In: Drug safety vol. 33 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	7.	Characteristics of orphan drug applications that fail to achieve marketing approval in the USA. [electronic resource] by Heemstra, Harald E Leufkens, Hubert G M Rodgers, R P Channing Xu, Kui Voordouw, Bettie C G Braun, M Miles Producer: 20110428 In: Drug discovery today vol. 16 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	8.	Determinants for successful marketing authorisation of orphan medicinal products in the EU. [electronic resource] by Putzeist, Michelle Heemstra, Harald E Garcia, Jordi Llinares Mantel-Teeuwisse, Aukje K Gispen-De Wied, Christine C Hoes, Arno W Leufkens, Hubert G M Producer: 20120801 In: Drug discovery today vol. 17 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)